Xapavir (Dolutegravir) 50 mg Tablets is a high-quality antiretroviral medicine manufactured by Cordium Pharmaceuticals Pvt. Ltd. for global pharmaceutical markets. Dolutegravir is an Integrase Strand Transfer Inhibitor (INSTI) widely used as part of combination antiretroviral therapy (ART) for the treatment of HIV-1 infection.
Mechanism of Action of Dolutegravir 50 mg
Dolutegravir works by inhibiting the HIV integrase enzyme, which the virus requires to insert its genetic material into human DNA. Specifically, it blocks the strand transfer step of viral DNA integration, preventing HIV from replicating inside host cells. This helps reduce viral load, preserve immune function, and improve long-term treatment outcomes.
Therapeutic Uses of Xapavir (Dolutegravir) 50 mg Tablets
Treatment of HIV-1 infection in adults and eligible adolescents.
Used only in combination with other antiretroviral medicines as part of a complete HIV treatment regimen.
Recommended in many national and international HIV treatment guidelines due to its high efficacy and strong resistance profile.
Key Benefits
Once-daily oral dosing (for many treatment regimens)
Potent viral suppression
High genetic barrier to resistance
Well-established safety and efficacy profile
Suitable for inclusion in first-line HIV treatment programs, according to many clinical guidelines.
Export Markets
Cordium Pharmaceuticals Pvt. Ltd. supplies Xapavir (Dolutegravir) 50 mg Tablets for regulated and emerging international markets, including:
🇰🇪 Kenya
🇳🇬 Nigeria
🇬🇭 Ghana
🇵🇭 Philippines
🇻🇳 Vietnam
🇦🇪 UAE
🇸🇦 Saudi Arabia
🇺🇿 Uzbekistan
🇰🇿 Kazakhstan
🇺🇸 USA
🇬🇧 UK
🇿🇦 South Africa
Why Choose Cordium Pharmaceuticals Pvt. Ltd.?
WHO-GMP quality-focused manufacturing
International export expertise
Reliable pharmaceutical supply chain
Regulatory documentation support
Bulk supply and private labeling opportunities
Commitment to high-quality generic medicines
Medical Disclaimer: Dolutegravir should be used only under the supervision of a qualified healthcare professional and always in combination with other antiretroviral medicines. It is not intended for use as monotherapy for HIV treatment. Treatment should follow local regulatory approvals and clinical guidelines.
